Evidence map›Paper›PMID 41144126›Full record

ReviewDiscover oncology2025

Advances in polycythemia vera treatment with targeted therapies and clinical trials.

Doaa Hassanien, Rashid A AlYafei, Omar H Metwally, Izzaldin Alremawi, Abdulla Khalid Al-Kaabi, Mohamed Elahtem, Talal Al-Sayed, Mohamed A Yassin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Doaa HassanienNeurology Department, Hamad Medical Corporation (HMC), P. O. Box 3050, Doha, Qatar. dh1906733@qu.edu.qa.
Rashid A AlYafeiCollege of Medicine, QU Health, Qatar University, P. O. Box 2713, Doha, Qatar.
Omar H MetwallyInternal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
Izzaldin AlremawiCollege of Medicine, QU Health, Qatar University, P. O. Box 2713, Doha, Qatar.
Abdulla Khalid Al-KaabiCollege of Medicine, QU Health, Qatar University, P. O. Box 2713, Doha, Qatar.
Mohamed ElahtemCollege of Medicine, QU Health, Qatar University, P. O. Box 2713, Doha, Qatar.
Talal Al-SayedCollege of Medicine, QU Health, Qatar University, P. O. Box 2713, Doha, Qatar.
Mohamed A YassinHematology Section, Medical Oncology, National Center for Cancer Care and Research (NCCCR), Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by excessive red blood cell production, leading to a heightened risk of thrombosis, hemorrhage, and progression to myelofibrosis. While traditional therapies such as phlebotomy and hydroxyurea have been used for disease management, they do not address the underlying pathophysiology or alleviate common symptoms like fatigue and pruritus. Recent advances in targeted therapies offer promising new options for PV treatment. This review explores novel therapeutic approaches currently under investigation, including hepcidin agonists, MDM2 inhibitors, histone deacetylase (HDAC) inhibitors, and LSD1 inhibitors. These therapies aim to correct hematopoietic dysregulation, reduce symptom burden, and improve long-term outcomes for PV patients. While clinical trials show encouraging results, further studies are needed to fully evaluate their safety, efficacy, and potential for broad clinical use. Ultimately, these emerging treatments could reshape the landscape of PV management by offering more personalized, effective options for patients.

Indexed as

Chronic myeloproliferative disorder (CMD)Clinical trialsHepcidin agonistsHistone deacetylase (HDAC) inhibitorsLSD1 inhibitorsMDM2 inhibitorsPolycythemia vera (PV)

Identifiers

PMID41144126
PMCPMC12559549

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.